In this QA, Premal H. Thaker, MD, MS, of @washumedicine.bsky.social unpacks the role of CDK2 inhibition in platinum-resistant ovarian cancer. #oncology #PROC #ovariancancer
Read more here: www.onclive.com/view/oral-ad...
Emi-Le generated durable responses and encouraging PFS with manageable safety in patients with aggressive adenoid cystic carcinoma. @harvardmed.bsky.social @danafarber.bsky.social @ascocancer.bsky.social #ASCO26 #hncsm #oncology
www.onclive.com/view/emiltat...
Subcutaneous blinatumomab led to high response rates across 2 dosing regimens in heavily pretreated patients with relapsed/refractory, Ph-positive B-ALL in a phase 1/2 trial #EHA2026 #leusm #oncology
Dive into the data: www.onclive.com/view/subcuta...
LB2501, an off-the-shelf in vivo dual-target CAR T-cell therapy, produced a 100% ORR at dose level 2 across DLBCL, MCL, and follicular lymphoma. #EHA2026 #lymsm #hematology
www.onclive.com/view/in-vivo...
Real-world data from the CIBMTR registry at #EHA2026 reinforce the impact of liso-cel in relapsed/refractory #MCL.
âś… ORR of 89% and CR rate of 79%
âś… Median DOR, PFS, and OS not reached
âś… Safety profile consistent with pivotal trial results
Learn more: www.onclive.com/view/real-wo...
In the BTK inhibitor–naive setting, the BTK degrader tacabrutideg was safe with antitumor activity in CLL and other B-cell malignancies #EHA2026 #leusm #oncology
Read more on cohort 1f of the phase 1 CaDAnCe-101 trial: www.onclive.com/view/tacabru...
WATCH: Mark D. Tyson, II, MD, MPH of @mayocliniccancer.bsky.social discusses data from a real-world study of blue light cystoscopy in high-risk NMIBC. #oncology #NMIBC #bladdercancer
www.onclive.com/view/dr-tyso...
🦴🚨 The FDA has accepted the BLA for ozekibart (INBRX-109) in patients with unresectable or metastatic conventional chondrosarcoma, marking a major regulatory milestone in a disease with no approved systemic therapies.
Read more ➡️ www.onclive.com/view/fda-acc...
#Sarcoma #Chondrosarcoma #Oncology
WATCH: Benjamin Croll, MD, of @foxchasecancer.bsky.social discusses research focused on understanding response to systemic therapy in RCC. #oncology #RCC #kcsm
www.onclive.com/view/dr-crol...
Treatment with subcutaneous blinatumomab generated high CR rates across 2 dosing regimens in pretreated, relapsed/refractory, Ph-positive B-ALL.
Updated ROCK-1 data at #EHA2026 show that rocbrutinib continues to deliver activity in R/R #MCL previously treated w/ a covalent BTK inhibitor. #lymsm
âś… ORR of 63.9%, including a 23.0% CR rate
âś… Median DOR of 16.46 months
âś… Median OS NR at 23.36 months of follow-up
onclive.com/view/rocbrut...
OncLive
OncLive
OncLive
LB2501, an off-the-shelf in vivo dual-target CAR T-cell therapy, produced a 100% ORR at dose level 2 across DLBCL, MCL, and follicular lymphoma.
Real-world data show liso-cel drives high response rates and durable benefit in relapsed/refractory MCL, including high-risk patients.
www.onclive.com
Tacabrutideg's safety profile was tolerable, and the drug had antitumor activity in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies.
